Lupin, Zydus Life shares fall up to 8% as US court sides with Astellas in Myrbetriq patent case
The ruling would be viewed as a negative development for Lupin and Zydus, as it effectively blocks their ability to market the generic drug in the US. Analysts suggest the companies may also face financial penalties.

What's Your Reaction?






